| abstract |
The present invention relates to a novel aqueous liquid pharmaceutical composition, with controlled release of buprenorphine or a buprenorphine analog, comprising at least one prodrug of low aqueous solubility of said buprenorphine or a buprenorphine analog, and at least one polymer having a linear backbone chosen from polyglutamates, polyaspartates, poly (meth) acrylates and polysaccharides, to which one or more hydrophobic groups are grafted. |